Scinai Immunotherapeutics Ltd.
SCNIHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Scinai Immunotherapeutics Ltd. focuses on Biotechnology services and products. Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. At a $764K market cap, Scinai Immunotherapeutics Ltd. ranks as a micro-cap company within healthcare. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Market Cap
$763,897
Beta
2.13
P/E (TTM)
0.02
P/E (Fwd)
—
EPS (TTM)
$28.07
EPS (Fwd)
—
ROE
-26.5%
ROA
-36.1%
Cash
$2.7M
Total Debt
$3.6M
Free CF
-$3.7M
52W Change
-96.1%
Annual Financials
Cash vs Debt
Where SCNI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SCNI finished 79.17% below its 150-day moving average ($3.60) and 84.38% below its 200-day moving average ($4.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCNI overbought or oversold?
At the October 20, 2026 close, SCNI's RSI(14) was 19.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $2.7M in cash, though total debt stands at $3.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$3.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, SCNI tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Scinai Immunotherapeutics Ltd. and its sector.